Large Retroperitoneal Lymph Node Associated with VTE in Disseminated Germ Cell Tumors
the Cancer Therapy Advisor take:
Large retroperitoneal lymph node (RPLN) is associated with venous thromboembolism (VTE) in patients with disseminated germ cell tumors (GCTs), providing better accuracy than high-risk Khorana score in this group, according to a recent study published in the Journal of Clinical Oncology.
Amirrtha Srikanthan, MD, of the Princess Margaret Cancer Centre in Toronto and fellow researchers looked at a training cohort of 216 patients with disseminated GCT who were receiving first-line chemotherapy from January 2000 to December 2010, with large RPLN defined as more than 5 centimeters in diameter.
Comparing predictive models using large RPLN with high-risk Khorana score in order to determine risk of VTE, the researchers found that the former method showed higher discriminatory accuracy, with further validation in a London cohort.
Twenty-one patients developed VTE during chemotherapy, and it was associated with large RPLN, high-risk Khorana score, intermediate- to poor-risk disease, and hospitalization.
“Prophylactic anticoagulation may be considered in high-risk patients,” the authors concluded. “Results should be validated in larger, prospective studies.”
RPLN is associated with VTE in patients with disseminated germ cell tumors.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma